KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ginkgo Bioworks Holdings (DNA) Cost of Revenue (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Cost of Revenue readings, the most recent being $14.8 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 476.64% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.4 million, a 81.64% increase, with the full-year FY2025 number at $28.9 million, changed N/A from a year prior.
  • Cost of Revenue hit $14.8 million in Q4 2025 for Ginkgo Bioworks Holdings, up from $8.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $81.8 million in Q4 2021 to a low of -$3.9 million in Q4 2024.
  • Median Cost of Revenue over the past 5 years was $10.0 million (2024), compared with a mean of $17.7 million.
  • Biggest five-year swings in Cost of Revenue: soared 1119.43% in 2021 and later crashed 94.13% in 2023.
  • Ginkgo Bioworks Holdings' Cost of Revenue stood at $81.8 million in 2021, then crashed by 88.29% to $9.6 million in 2022, then skyrocketed by 89.05% to $18.1 million in 2023, then crashed by 121.72% to -$3.9 million in 2024, then skyrocketed by 476.64% to $14.8 million in 2025.
  • The last three reported values for Cost of Revenue were $14.8 million (Q4 2025), $8.2 million (Q3 2025), and $5.4 million (Q2 2025) per Business Quant data.